Brainstorm Cell Therapeutics Inc To Discuss The Company's Biologics License Application (BLA) for NurOwn(®) Transcript
Greetings, and welcome to the BrainStorm Cell Therapeutics conference call. (Operator Instructions) As a reminder, this call is being recorded. And I would now like to introduce your host for today's call, Michael Wood of LifeSci Advisors. Mr. Wood, you may begin.
Good morning, and thank you for joining us. Earlier today, BrainStorm issued a press release announcing that the FDA will hold an Advisory Committee Meeting to review the company's Biologics License Application for NurOwn in the treatment of ALS. This announcement will be the topic of today's call.
Before passing it off to the company for prepared remarks, I would like to remind listeners that this conference call will contain numerous statements, descriptions, forecasts, and projections regarding BrainStorm Cell Therapeutics and its potential future business operations and performance, statements regarding the market potential for the treatment of neurodegenerative disorders such as ALS, the sufficiency of the company's existing capital resources for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
